BioMarin Pharmaceutical Inc (BMRN) FY2026 YTD Q2 P&L / Income Statement

BioMarin Pharmaceutical Inc (BMRN) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Contract with Customer, Sales Channel. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

1,755,916,000 US dollars

Cost of sales

397,794,000 US dollars

Gross profit (calculated)

1,358,122,000 US dollars

Operating expenses (calculated)

1,117,562,000 US dollars

INCOME FROM OPERATIONS

240,560,000 US dollars

Other income (expense), net (calculated)

negative 37,973,000 US dollars

INCOME BEFORE INCOME TAXES

202,587,000 US dollars

Provision for income taxes

52,298,000 US dollars

NET INCOME

150,289,000 US dollars

Royalty and other revenues

11,445,000 US dollars

ALDURAZYME - Marketed by Sanofi

80,281,000 US dollars

Products excluding ALDURAZYME - Marketed by Company

1,664,190,000 US dollars

Selling, general and administrative

653,839,000 US dollars

Research and development

385,748,000 US dollars

Intangible asset amortization

77,975,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.